Publications

Collaborations and publications are strong proofs of the relevance of our research.

Dr. Laurent Meijer: H-Factor (78), ResearchGate score: 48.64

Cystic Fibrosis (CF)

  1. Marteyn, B.S., Burgel, P.R., Meijer, L. and Witko-Sarsat, V., 2017. Harnessing neutrophil survival mechanisms during chronic infection by Pseudomonas aeruginosa: novel therapeutic targets to dampen inflammation in cystic fibrosis. Front. Cell. Infect. Microbiol. 7, 243.
  2. Meijer, L., Nelson, D., Riazanski, V., Gabdoulkhakova, A.G., Hery-Arnaud, G., Leberre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., Gueganton, L., Dorothée, G., Prochazkova, M., Hall, B., Kulkarni, A.B., Gray, R.D., Rossi, A.G., Witko-Sarsat, V., Norez, C., Becq, F., Ravel, D., Mottier, D. and Rault, G., 2016. Modulating innate and adaptative immunity by (R)-roscovitine: potential therapeutic opportunity in cystic fibrosis J. Innate Immunity 8, 330-349.
  3. Riazanski, V., Gabdulkhakova, A.G., Boynton, L.S., Eguchi, R.R., Deriy, L.V., Hogarth, D.K., Loaëc, N., Oumata, N., Galons, H., Brown, M.E., Shevchenko, P., Gallan, A.J., Yoo, S.G., Naren, A.P., Villereal, M.L., Beacham, D.W., Bindokas, V.P., Birnbaumer, L., Meijer, L. and Nelson, D.J., 2015. TRPC6 channel translocation into phagosomal membrane augments phagosomal function. Proc. Natl. Acad. Sci. USA 112, E6486-6495.
  4. A Phase II, dose ranging, multicenter, double-blind, placebo controlled study to evaluate safety and effects of (R)-roscovitine in subjects with Cystic Fibrosis, homozygous for the F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa, a study involving 36 CF patients (24 treated, 12 controls). ANSM authorization Sept. 15, 2015. https://clinicaltrials.gov/ct2/show/NCT02649751?term=roscovitine&rank=1
  5. Norez, C., Vandebrouck, C., Bertrand, J., Noel, S., Durieu, E., Oumata, N., Galons, H., Antigny, F., Chatelier, A., Bois, P., Meijer, L. and Becq, F., 2014. Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. Br. J. Pharmacol. 171, 4831-4849.